These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases. Hansson MG; Gattorno M; Forsberg JS; Feltelius N; Martini A; Ruperto N Arch Dis Child; 2012 Jun; 97(6):561-3. PubMed ID: 22362719 [No Abstract] [Full Text] [Related]
4. The needs of the few. Nature; 2010 Jul; 466(7303):160. PubMed ID: 20613796 [No Abstract] [Full Text] [Related]
5. Bridging the gap: improving clinical development and the regulatory pathways for health products for neglected diseases. Bollyky TJ; Cockburn IM; Berndt E Clin Trials; 2010 Dec; 7(6):719-34. PubMed ID: 21109581 [TBL] [Abstract][Full Text] [Related]
6. The ethics of non-inferiority trials. Soliman EZ Lancet; 2008 Mar; 371(9616):895; author reply 896-7. PubMed ID: 18342675 [No Abstract] [Full Text] [Related]
8. Small biotechs raring to cash in on the orphan disease market. Hersher R Nat Med; 2012 Mar; 18(3):330-1. PubMed ID: 22395682 [No Abstract] [Full Text] [Related]
9. Creating more paths to hope. Hale V Newsweek; 2004 Dec; 144(23):80. PubMed ID: 15605728 [No Abstract] [Full Text] [Related]
10. Sample size estimation for non-inferiority trials of time-to-event data. Crisp A; Curtis P Pharm Stat; 2008; 7(4):236-44. PubMed ID: 17583558 [TBL] [Abstract][Full Text] [Related]
11. Management of rare diseases. Walshe JM QJM; 2006 Feb; 99(2):123-4. PubMed ID: 16428334 [No Abstract] [Full Text] [Related]
12. Bayesian sample size calculations for a non-inferiority test of two proportions in clinical trials. Daimon T Contemp Clin Trials; 2008 Jul; 29(4):507-16. PubMed ID: 18201944 [TBL] [Abstract][Full Text] [Related]
13. Ethics of large clinical trials in rapidly lethal diseases. Mawson AR Lancet; 2003 Apr; 361(9365):1296. PubMed ID: 12699970 [No Abstract] [Full Text] [Related]
14. Ethics of large clinical trials in rapidly lethal diseases. Rule S; Copplestone A Lancet; 2003 Apr; 361(9365):1297. PubMed ID: 12699974 [No Abstract] [Full Text] [Related]
15. Methods for one-sided testing of the difference between proportions and sample size considerations related to non-inferiority clinical trials. Dann RS; Koch GG Pharm Stat; 2008; 7(2):130-41. PubMed ID: 17526060 [TBL] [Abstract][Full Text] [Related]
16. The ethics of non-inferiority trials. Chuang-Stein C; Beltangady M; Dunne M; Morrison B Lancet; 2008 Mar; 371(9616):895-6; author reply 896-7. PubMed ID: 18342677 [No Abstract] [Full Text] [Related]
17. Financing drug discovery for orphan diseases. Fagnan DE; Gromatzky AA; Stein RM; Fernandez JM; Lo AW Drug Discov Today; 2014 May; 19(5):533-8. PubMed ID: 24269746 [TBL] [Abstract][Full Text] [Related]
18. Ethics of large clinical trials in rapidly lethal diseases. Perkins P Lancet; 2003 Apr; 361(9365):1296-7. PubMed ID: 12699972 [No Abstract] [Full Text] [Related]
19. [Methodology and management of clinical trials with small number of patients for rare diseases]. Micallef J Presse Med; 2012 May; 41 Suppl 1():S32-4. PubMed ID: 22483773 [No Abstract] [Full Text] [Related]
20. Ethics of large clinical trials in rapidly lethal diseases. Thwaites G; Thwaites L; Hien TT; Farrar J Lancet; 2003 Apr; 361(9365):1296. PubMed ID: 12699971 [No Abstract] [Full Text] [Related] [Next] [New Search]